Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021.
Questions
- Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19)
- Could you tell us a little about firibastat and the rationale for its potential use in heart failure post myocardial infarction? (1.44)
- What were the aims and design of the QUORUM clinical study? (3.00)
- What were the efficacy and safety endpoints and how well were they achieved? (4.36)
- What will be the clinical impact of these findings? (7.13)
Speaker disclosures: Prof. Gilles Montalescot declares research funds for the Institution or fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cell Prothera, CSL Behring, Europa, Idorsia, IRIS -Servier, Medtronic, MSD, Novartis, Pfizer, Quantum Genomics and Sanofi-Aventis.
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Prof. Gilles Montalescot as a highlight of ESC 2021, August 2021.
